| Alphabet / GOOGL | Aktiv | 20% stock sleeve target | Åbn |
| TSMC / TSM | Aktiv | 20% stock sleeve target | Åbn |
| ASML Holding / ASML | Priority watch | Provisional 102/125 after Q2; no third position before normalized valuation and risk comparison | Åbn |
| Micron / MU | Priority watch | 99/125 after Q3 FY2026; full re-score needed before buy status | Åbn |
| Broadcom / AVGO | Priority watch | 98/125 after Q2 FY2026; valuation and customer concentration block buy status | Åbn |
| Arista / ANET | Provisional 105 | Q2 validates networking quality; concentration, margin mix and valuation block new capital | Åbn |
| NVIDIA / NVDA | Provisional 104 | Q2 validates elite operations; USD 366bn commitments plus customer-linked financing and valuation block a third position | Åbn |
| Nebius / NBIS | High-risk research | USD 5bn convertibles fund growth but deepen debt, accretion and dilution risk; no score or capital | Åbn |
| Palo Alto Networks / PANW | Priority research | Cybersecurity platform screen; organic/acquired growth, GAAP/SBC, goodwill, leverage and valuation remain open | Åbn |
| IMAX / IMAX | Research | Entertainment/IP screen; Q2 quality signal but no score or capital | Åbn |
| Adobe / ADBE | Priority research | Q2 growth and cash flow verified; AI disruption and valuation remain open | Åbn |
| GE Vernova / GEV | Priority research | Q2 validates grid/turbine demand and FCF; unscored until normalized margin and valuation work | Åbn |
| Ciena / CIEN | Priority research | Fiscal Q2 validates optical networking growth; unscored with 34% two-customer concentration | Åbn |
| Vertiv / VRT | Priority watch | Q2 quality upgrade to 98/125; valuation and cycle work still block new capital | Åbn |
| UiPath / PATH | Watch | Agentic automation watch; 88/125 and not buyable now | Åbn |
| Microsoft / MSFT | Watch | FY2026 Q4 validates demand; still unscored pending capex/FCF and valuation work | Åbn |
| Meta / META | Watch | Q2 revenue +28%, but USD 31.1bn capex left only USD 0.8bn FCF; unscored | Åbn |
| Novo Nordisk / NVO | Watch | Healthcare/obesity drugs theme | Åbn |
| Visa / V | Priority research | Fiscal Q3 preserves the payments-quality case; compare with MA/SPGI and refresh valuation | Åbn |
| NOW | Priority research | Q2 demand verified; unscored pending GAAP margin, SBC, acquisitions and valuation | Åbn |
| TSLA | Rejected | Q2 margin/FCF does not support a robotics-led sleeve case | Åbn |
| Bloom Energy / BE | High-risk watch | Q2 upgrade to 82/125; 73% customer concentration blocks eligibility | Åbn |
| CDNS, LRCX, ARM | Priority research | Latest results strengthen the EDA/IP/equipment map; ARM remains 91 and the others unscored | Åbn |
| FICO | Deprioritized | Strong Q3 growth, but debt-funded repurchases fail the current capital-allocation check | Åbn |